Published in Blood on November 01, 1977
Reduced thrombin binding and aggregation in Bernard-Soulier platelets. J Clin Invest (1978) 1.22
Acquired Bernard-Soulier syndrome. Evidence for the role of a 210,000-molecular weight protein in the interaction of platelets with von Willebrand factor. J Clin Invest (1985) 0.87
Normal and abnormal hemostasis--an integrated view. A review. Am J Pathol (1978) 0.75
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood (1995) 16.81
The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell (1991) 8.98
The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature (1990) 5.24
Acute promyelocytic leukemia. N Engl J Med (1993) 4.63
All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood (1990) 4.36
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol (1998) 2.74
Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 2.54
Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med (1996) 2.38
The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene (1995) 2.23
Induction of the PML protein by interferons in normal and APL cells. Leukemia (1995) 2.05
Increase of endothelial cell growth by sera from diabetic patients with proliferative retinopathy. Lancet (1989) 2.05
Is there a limit to the normality of blood products? Hematol J (2000) 2.00
Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med (1999) 1.91
Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature (1990) 1.87
PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood (1993) 1.82
Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia (2006) 1.77
Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines. Proc Natl Acad Sci U S A (1987) 1.77
Bernard-Soulier syndrome: a new platelet glycoprotein abnormality. Its relationship with platelet adhesion to subendothelium and with the factor VIII von Willebrand protein. J Lab Clin Med (1976) 1.58
Some chronic lymphocytic leukemia cells bearing surface immunoglobulins share determinants with T cells. Eur J Immunol (1978) 1.58
PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci U S A (1994) 1.57
Neutrophilic dermatoses during granulocytopenia. Arch Dermatol (1995) 1.56
Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol (2000) 1.56
Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia (2000) 1.55
A combination of HLA-DQ beta Asp57-negative and HLA DQ alpha Arg52 confers susceptibility to insulin-dependent diabetes mellitus. J Clin Invest (1990) 1.51
Specific mucosal erosions in hypereosinophilic syndrome. Evidence for eosinophil protein deposition. Arch Dermatol (1996) 1.48
Acquired IgG antibody occurring in a thrombasthenic patient: its effect on human platelet function. Blood (1978) 1.47
Immunochemical evidence for protein abnormalities in platelets from patients with Glanzmann's thrombasthenia and Bernard-Soulier syndrome. J Clin Invest (1980) 1.45
Phase I trials in cancer treatment. The maximum tolerated dose: a barbarian guideline. Hematol J (2000) 1.41
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol (2000) 1.37
A molecular defect in thrombasthenic platelets. J Clin Invest (1975) 1.36
A haplotype study of HLA complex with special reference to the HLA-DR series and to Bf. C2 and glyoxalase I polymorphisms. Tissue Antigens (1978) 1.35
The association of the HL-A antigens with diseases. Clin Immunol Immunopathol (1974) 1.34
Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia (2000) 1.31
Molecular basis of Glanzmann's Thrombasthenia and current strategies in treatment. Blood Rev (2002) 1.31
Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol (1990) 1.30
All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood (1990) 1.30
The relationship between nasopharyngeal carcinoma and the HL-A system among Tunisians. Int J Cancer (1975) 1.30
Human T cell gamma genes are frequently rearranged in B-lineage acute lymphoblastic leukemias but not in chronic B cell proliferations. J Exp Med (1987) 1.28
Demonstration of two forms of calcium pumps by thapsigargin inhibition and radioimmunoblotting in platelet membrane vesicles. J Biol Chem (1991) 1.27
The HL-A system sub-loci and their importance in transplantation. Transplant Proc (1969) 1.27
Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: binding, internalization, degradation, and biological effects. J Cell Physiol (1991) 1.23
Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am (2000) 1.22
Regulation of transcription of the human T cell antigen receptor delta chain gene. A T lineage-specific enhancer element is located in the J delta 3-C delta intron. J Exp Med (1990) 1.22
Availability of platelet Factor 3 and activation of factor XII in thrombasthenia. Nature (1965) 1.20
Monoclonal antibody to human platelet glycoprotein I. I. Immunological studies. Br J Haematol (1981) 1.18
Human transplantation antigens: the HL-A (Hu-1) system and its homology with the mouse H-2 system. Transplantation (1968) 1.17
Monoclonal antibody to human platelet glycoprotein I. II. Effects on human platelet function. Br J Haematol (1981) 1.15
Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol (2004) 1.13
Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia (2003) 1.13
Defective alpha-granule production in megakaryocytes from gray platelet syndrome: ultrastructural studies of bone marrow cells and megakaryocytes growing in culture from blood precursors. Am J Pathol (1981) 1.11
High pp60c-src level in human platelet dense bodies. Blood (1989) 1.11
Effect of prostacyclin (PGI2) on platelet adhesion to rabbit arterial subendothelium. Prostaglandins (1978) 1.11
Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta (1985) 1.11
Problem of positive complement-fixation reactions with the Reiter treponeme in the absence of syphilis. Role of a polysaccharide antigen. Br J Vener Dis (1965) 1.11
Thrombin induces endothelial cell growth via both a proteolytic and a non-proteolytic pathway. Biochem J (1994) 1.10
Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med (1986) 1.10
All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol (2001) 1.09
Separation of anti-Ia (I-region associated antigens) from anti-H-2 antibodies in complex sera, by absorption on blood platelets. description of three new Ia specificities. Tissue Antigens (1976) 1.09
Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient. Leukemia (1994) 1.08
Aggregation, adhesion, and viscous metamorphosis of platelets in congenital fibrinogen deficiencies. J Lab Clin Med (1966) 1.07
Regulation of calcium accumulation and efflux from platelet vesicles. Possible role for cyclic-AMP-dependent phosphorylation and calmodulin. Biochim Biophys Acta (1983) 1.07
Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. Am J Med (1990) 1.07
Predominant expression of circulating CD3+ lymphocytes bearing gamma T cell receptor in a prolonged immunodeficiency after allogeneic bone marrow transplantation. J Clin Invest (1988) 1.06
C8 deficiency in a family with xeroderma pigmentosum. Lack of linkage to the HLA region. Clin Immunol Immunopathol (1977) 1.06
The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. Oncogene (1994) 1.05
Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia (2002) 1.05
Clopidogrel: a review of its mechanism of action. Platelets (1998) 1.05
Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia (2004) 1.05
[Criteria for assessing granulocytic or platelet cytopenia caused by drugs. Results of consensus meetings]. Nouv Rev Fr Hematol (1987) 1.04
Gray platelet syndrome: alpha-granule deficiency. Its influence on platelet function. J Lab Clin Med (1981) 1.03
New functions for platelets and their pathological implications. Int Arch Allergy Appl Immunol (1985) 1.03
Selective pressure on HL-A polymorphism. Nature (1974) 1.02
Coordination of organ growth: principles and outstanding questions from the world of insects. Trends Cell Biol (2013) 1.02
Interaction of blood platelets with a microfibrillar extract from adult bovine aorta: requirement for von Willebrand factor. Proc Natl Acad Sci U S A (1983) 1.02
Retinoic acid therapy for promyelocytic leukaemia. Lancet (1989) 1.00
Small doses of ARA-C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells? Br J Haematol (1982) 1.00
The retinoic acid receptor alpha gene is rearranged in retinoic acid-sensitive promyelocytic leukemias. Leukemia (1990) 1.00
Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells--inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost (1988) 0.99
Biochemical characterization of plasma membranes and intracellular membranes isolated from human platelets using Percoll gradients. Biochim Biophys Acta (1986) 0.99
Interaction between platelets and von Willebrand factor provides a new scheme for primary haemostasis. Nat New Biol (1973) 0.98
[A new antigen of the system HL-A (Hu-1): the antigen 15, possible allele of the antigens 1, 11, 12]. Nouv Rev Fr Hematol (1968) 0.98
Human T cell clones use a CD3-associated surface antigen recognition structure to exhibit both NK-like and allogeneic cytotoxic reactivity. J Immunol (1987) 0.97